Plain-English translation of NCT07247188 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Sickle Cell Disease research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new pneumococcal vaccine called in children and teens ages 2 to 17 who have sickle cell disease. The vaccine is designed to protect against 21 different types of pneumococcal bacteria that can cause serious infections. The study will compare this new medication with a similar vaccine that protects against 20 types, to see which one is safer and how well each one works in people with sickle cell disease.
Children with sickle cell disease are at higher risk for serious pneumococcal infections, so they need strong protection from vaccines. This trial exists to find out if the new treatment offers better protection than older vaccines available today.
You likely qualify if…
You likely don't qualify if…
You will receive one injection of either the new vaccine () or the comparison vaccine () — you won't know which one you get. The study lasts up to 6 months, during which you'll have scheduled visits so researchers can check how you're doing and watch for any side effects. The visits will include health checks and possibly blood tests to see how your body responds to the vaccine.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
United States